DIRS.INFO The most relevant business & tech news

☆ This under-the-radar biopharma stock could more than double, Goldman Sachs says
▼ + stars: | 2023-11-20 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

Iovance Biotherapeutics ' star asset could propel its stock to new heights, according to Goldman Sachs. IOVA YTD mountain IOVA YTD chart Iovance specializes in developing autologous tumor-infiltrating lymphocyte, or TIL, therapies for solid tumor cancers using its lead asset lifileucel. As a catalyst, analyst Andrea Tan pointed to the upcoming approval of the company's first such treatment, which is slated to be reviewed by February 2024. "With accelerated approval, lifileucel would be the first cell therapy approved for solid tumors and IOVA is preparing for commercial launch," she wrote. The analyst added that lifileucel, a "best-in-class therapy," has the potential to become the standard of care in treating melanoma.

Persons: Iovance Biotherapeutics, Goldman Sachs, Andrea Tan, Tan, CNBC's Michael Bloom Locations: Friday's

☆ Goldman says this little-known biotech stock could more than double
▼ + stars: | 2023-08-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Clinical-stage biopharmaceutical company Sagimet Biosciences could see its treatments reach a breakout stage, which could send its share price soaring, according to Goldman Sachs. The stock has been publicly traded since July 14, and it's trading slightly below its IPO level. Investors are focused on upcoming biopsy results of the second phase of the denifanstat study on liver fat levels, said Tan. Positive results from this phase would support advancement into a pivotal phase three study, she added. The "role of FASN in other indications could offer upside," Tan noted.

Persons: Goldman Sachs, NASH, Andrea Tan, Tan, Denifanstat, FASN, — CNBC's Michael Bloom Organizations: Sagimet Biosciences

☆ Madrigal NASH drug meets goals in much-awaited trial, shares surge
▼ + stars: | 2022-12-19 | by ( ) www.reuters.com time to read: +1 min

Dec 19 (Reuters) - Madrigal Pharmaceuticals' (MDGL.O) experimental drug for fatty liver disease met both of the main goals in a highly anticipated late-stage study, it said on Monday, sending the company's shares soaring over 200%. The positive data sets the stage for the drug, resmetirom, to become the first approved treatment for NASH, or nonalcoholic steatohepatitis, a disease that affects about 5% of adults in the United States. Data from the trial shows a lower 80 milligram dose helped 26% of patients reach NASH resolution, compared to 30% for a higher 100 milligram dose, and 10% for placebo. NASH is a form of nonalcoholic fatty liver disease, characterized by the organ developing fibrosis or scarring, which can progress to cirrhosis and liver failure. The company plans to file a marketing application seeking accelerated approval for the drug in the first half of 2023.

☆ Goldman Sachs says this biotech stock can double on treatment against childhood brain tumor
▼ + stars: | 2022-12-05 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors looking for exposure to the biotechnology sector should consider buying Day One Biopharmaceuticals , a stock that can more than double from current levels, according to Goldman Sachs. Analyst Andrea Tan initiated coverage on the biotechnology stock with a buy rating, saying positive data in the first quarter on a possible treatment for childhood brain tumors could unlock a multibillion-dollar sales opportunity. Initial reads on tovorafenib, a treatment for pediatric low-grade glioma, have so far been promising, according to the note. Tovorafenib is under evaluation in a clinical trial called FIREFLY-1 for relapsed pLGG, with data expected in the first quarter of 2023. The analyst expects positive topline data from the trial could serve as a catalyst for the stock and "support a path to approval" for the therapy.

Search resuls for: "Andrea Tan"

4 mentions found